CM
KNSA icon

Capula Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Capula Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-41,242
Closed -$814K – 562
2024
Q1 		$814K Buy
+41,242
New +$805K 0.02% 132
2023
Q4 		– Sell
-51,340
Closed -$892K – 437
2023
Q3 		$892K Buy
+51,340
New +$865K 0.02% 246

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capula Management's KNSA Position: Q2 2024 in Review

Capula Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2024, closing a stake of 41,242 shares — an estimated $814K sold.

Capula Management first reported a position in KNSA in Q3 2023 and held it in 2 quarters. The position peaked at $892K in Q3 2023. 133 funds tracked by Wall St. Rank hold KNSA as of Q2 2024.

  • Capula Management reported no remaining Kiniksa Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Capula Management sold 41,242 Kiniksa Pharmaceuticals shares in Q2 2024, an estimated $814K.
  • Capula Management first reported a position in Kiniksa Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Capula Management's Kiniksa Pharmaceuticals position peaked at $892K in Q3 2023.
  • 133 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2024.

Based on Capula Management's 13F filing for Q2 2024, filed 5 Aug 2024.